Effect of deferoxamine alone and combined with pyrimethamine on acute toxoplasmosis in mice
Journal of the Egyptian Society of Parasitology. 1999; 29 (3): 791-803
em Inglês
| IMEMR
| ID: emr-51187
ABSTRACT
The standard regimen of treatment for toxoplasmosis is pyrimethamine with sulfadiazine. However, it is not suitable in some conditions and non-tolerable in AIDs patients. Deferoxamine [DFO], an iron chelator, is well tolerated clinically in transfusion induced-iron overload. The present study had shown that DFO is a promising drug against acute toxoplasmosis in mice. Three doses of 200, 300 and 400 mg/kg DFO were used either alone or in combination with pyrimethamine. Singly, it was effective in a dose-related response with the resultant of 70% protection of infected mice. When DFO was combined with a low minimally effective dose of pyrimethamine, a 100% protection was recorded with the prolongation in duration of survival of mice. Different possible mechanisms of action of DFO against Toxoplasma gondii were discussed
Buscar no Google
Índice:
IMEMR (Mediterrâneo Oriental)
Assunto principal:
Pirimetamina
/
Doença Aguda
/
Desferroxamina
/
Quimioterapia Combinada
/
Camundongos
Limite:
Animais
Idioma:
Inglês
Revista:
J. Egypt. Soc. Parasitol.
Ano de publicação:
1999
Similares
MEDLINE
...
LILACS
LIS